💊Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
Tokyo, March 26, 2018 — Mitsubishi Tanabe Pharma Corporation (TSE: 4508, Mitsubishi Tanabe Pharma) and Hitachi, Ltd. (TSE: 6501, Hitachi) today announced that they have initiated collaborative creation for improving the efficiency of clinical trials for the development of new drugs.
The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi’s advanced digital technology such as AI (1), aiming to shorten the period for development of new drugs and reduce development cost, while improving the probability of successful development.
https://www.mt-pharma.co.jp/e/release/nr/2018/pdf/e_MTPC180326.pdf